Recruiting NCT06603506
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: tumour and blood samples.
- Who it may be relevant to
- Registry conditions: Endometrial Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study comprises 3 stages: 1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.
Interventions
- Other tumour and blood samples
Tumour and blood samples
Primary outcome measures
- Rate of establishment of exploitable tumor organoid lines [Time frame: through study completion, an average of 3 years]
Eligibility criteria
Inclusion criteria
- Patient aged 18 years or more
- Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
- Patient with localized endometrial cancer, presenting:
- A high-grade endometrioid histological type and/or
- P53 mutation and/or
- a non-endometrioid histological type regardless of P53 status.
- Patient affiliated to a social security scheme
- Information and signature of informed consent prior to any specific study procedure
Exclusion criteria
- Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
- Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Centre François Baclesse — Caen
Publications
- Gall GL, Cherifi F, Divoux J, Florent R, Christy F, Leconte A, San C, Devillers A, Desmartin G, Lecouflet L, Clarisse B, Ballesta S, Thorel L, Dubois B, Harter V, Rousseau N, Gaichies L, Martin-Francoise S, Le Brun JF, Dolivet E, Rouzier R, Jeanne C, Blanc-Fournier C, Figeac M, Leman R, Castera L, Poulain L, Weiswald LB, Joly F. The PENDOR study: establishment of a panel of patient-derived tumor o PMID 39934735
Identifiers
NCT: NCT06603506 · 2024-A01206-41 · 2024-A01206-41